Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board

Entheon

Dr. David Erritzoe to provide guidance on psychopharmacological research Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College’s Center for Psychedelic Research, has been […]

Read More…